August 28th 2023
With an increased incidence of this sexually transmitted infection, a review of an older antibiotic for treatment has shown some clinical benefits in other countries.
July 31st 2023
The vaccine has been approved since late 2019 for adults age 18 and older.
July 26th 2023
The phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.
The update refreshes the organization's 2022 guidance on HIV, viral hepatitis, and STI prevention, diagnosis, treatment, and care for key populations, focusing on people in prisons and other closed settings.
April 7th 2023
When taken within 3 days, doxycycline given post-exposure (doxy-PEP) decreased the incidence rates of syphilis, gonorrhea, and chlamydia significantly.
Burden of HIV in the USA and Associated Symptoms
Mycobacterium tuberculosis in Patients With HIV Carries Mortality Risk
Relying solely on blood tests means clinicians may miss cases of potentially deadly M tuberculosis—and waiting days to treat suspected cases could prove fatal.
Long-Acting ART, Islatravir, and Capsid Inhibitors
Ian Frank, MD, discusses upcoming treatments for people with HIV.
People Facing HIV Stigma Are Less Likely To Make Their Next Care Visit
Patients facing HIV stigma may encounter difficulties with retention in care.
George Hanna, MD: Islatravir Presentations at CROI 2020
George Hanna, MD, vice president and therapeutic head of infectious diseases at Merck Laboratories, discusses data from CROI 2020 on islatravir.
A Modeling Study Points the Way to Stopping HIV Spread
The US government has ambitious goals to expand the number of people tested and treated for HIV in the coming years. A new study details the best interventions to make the biggest difference for the most people.
What "Ending the HIV Epidemic" Entails
Ian Frank, MD, explains the "Ending the Epidemic" initiative.
The HIV Vaccine Landscape
Colleen Kelley, MD, MPH, describes the current state of HIV vaccine efforts.
Virus-Delivered Anti-HIV Antibody Shows Promise in NIH Study
An antibody gene delivered by a harmless virus produced anti-HIV antibodies for a sustained period.
PrEP Coverage Associated with Decreased HIV Diagnoses
HIV pre-exposure prophylaxis appears to be making a difference, according to new research, which showed an association between increases in PrEP coverage and decreases in HIV diagnosis rates in the United States.
FLAIR Trial Results Advance Possibility for Long-Acting ART
A new study results demonstrate that a cabotegravir/rilpivirine injectable, delivered monthly, is noninferior to standard daily oral antiretroviral therapy and is well tolerated by patients.
Trial Data Released for Investigational HIV-1 Capsid Inhibitor
Data from clinical and preclinical studies on the use of the investigational HIV-1 capsid inhibitor GS-6207 were presented via 3 posters at CROI 2020.
The Importance of Youth HIV Prevention
Colleen Kelley, MD, MPH, discusses the importance of targeted youth HIV prevention measures.
Onyema Ogbuagu, MD: DISCOVER Week 96 Results
Contagion® spoke to Onyema Ogbuagu, MD, who presented the week 96 results from the DISCOVER study evaluating F/TAF and F/TDF.
DISCOVER 96 Week Results Back F/TAF Efficacy
There was a statistically significant difference in renal safety which favored F/TAF over F/TDF at Week 96.
The London Patient Remains in HIV Remission After 30 Months
The abstract authors report that both HIV viral load in plasma and proviral HIV DNA in CD4 cells have remained below levels of detection for up to 30 months.
Including Women in HIV Research
Ian Frank, MD, discusses the need to include women in HIV research.
Steffanie Strathdee, PhD: Preventing HIV Among People Who Inject Drugs
“There are structural drivers that are impeding prevention and treatment among people who inject drugs,” Strathdee said in an interview with Contagion®.
Cabotegravir and Rilpivirine Maintains Efficacy in FLAIR 96-Week Data
New Week 96 data from the FLAIR study indicate that once-monthly injections of cabotegravir and rilpivirine remains non-inferior and safe when compared with the daily, oral 3-drug regimen of ABC/DTG/3TC.
Prenatal Care, Universal Syphilis Screening Critical for US Women
A team of investigators hypothesized that prevalent syphilis infection in women with and without HIV may be a way to identify individuals who are at an elevated risk of a stillbirth over time.
Gaps Remain in Immediate ART Initiation in NYC Clinics
Despite the high level of knowledge surrounding immediate initiation of ART, the practice is not yet the standard of care across clinics in NYC.
GS-9722 Generally Safe, Well-Tolerated in Two Studies
Investigators conducted 2 studies on intravenously administered GS-9722, 1 in HIV-negative participants and 1 in virally suppressed people with HIV.
"Kick and Kill" Therapy Plus ART Evaluated in New Study
Getting rid of the latent reservoir of HIV is a key part of the quest to cure HIV, but the latest study examining the kick and kill method plus ART showed no effect compared with ART alone.
Barriers to PrEP Implementation
Colleen Kelley, MD, MPH, describes barriers to the implementation of HIV pre-exposure prophylaxis.
How are PEPFAR Countries Implementing PrEP?
A recent report discusses the expansion of pre-exposure prophylaxis into the 35 PEPFAR supported early program adopters from October 2016 to September 2018.
Examining the Factors Behind HIV Reemergence
New research pinpoints some of the factors involved in HIV reemergence after cessation of antiretroviral therapy, as well as possible ways to stop the process.
School STI Services Raise Complications of HIPAA Confidentiality
Clinicians accustomed to HIPAA guidelines may not be aware of changes in confidentiality when they make contact with school health care services.
Reflecting on HIV Diagnosis
Jason Tokumoto, MD, reflects on the ways people respond to HIV diagnosis.
Dolutegravir Recommended for Treatment-Naive Expectant Women
Concerns over the possibility of increased neural-tube defects and weight gain on dolutegravir are outweighed by the much lower rates of HIV transmission from mother to baby than are seen with efavirenz.
Interviews Show Mixed HPV Knowledge Among Young MSM
A new study has identified that misinformation and limited clinician communication around HPV risk among young men who have sex with men some of the barriers to HPV vaccination.
2 Clarke Drive Cranbury, NJ 08512